Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.
Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

Next Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The U.S. hasn’t seen syphilis numbers this high since 1950. Other STD rates are down or flat

The U.S. hasn’t seen syphilis numbers this high since 1...

Jan 30, 2024

vTv announces Phase III plans for type 1 diabetes drug cadisegliatin

vTv announces Phase III plans for type 1 diabetes drug ...

Aug 14, 2023

Sanofi and Biovac partner to produce polio vaccines in Africa

Sanofi and Biovac partner to produce polio vaccines in ...

Jun 22, 2024